Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Piazza

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Cancers|September 9, 2022
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple MyelomaAnna Fregnani, Lara Saggin, Ketty Gianesin, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2015
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic LeukemiaAndrea Visentin, Monica Facco, Federica Frezzato, et al.
Plos One|October 3, 2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cellsSabrina Manni, Alessandra Brancalion, Elisa Mandato, et al.
British Journal of Haematology|April 19, 2017
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cellsVeronica Martini, Cristina Gattazzo, Federica Frezzato, et al.
Cancers|November 13, 2021
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic LeukemiaFederica Frezzato, Andrea Visentin, Filippo Severin, et al.
Cancer Reports (Hoboken, N.J.)|April 25, 2024
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenarioNicolò Danesin, Greta Scapinello, Dorella Del Prete, et al.
Hematological Oncology|July 24, 2019
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemiaAndrea Visentin, Marina Deodato, Francesca R Mauro, et al.
Scientific Reports|May 2, 2025
A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cellsCristina Poggiana, Alessandro Francesco Piazza, Cristina Catoni, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
European Journal of Haematology|October 20, 2022
IDH2<sup>R172</sup> mutation in angioimmunoblastic T-cell lymphoma: A retrospective multicenter case seriesMarcello Riva, Maria Chiara Tisi, Roberta Bertorelle, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Cancers|September 9, 2022
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple MyelomaAnna Fregnani, Lara Saggin, Ketty Gianesin, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2015
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic LeukemiaAndrea Visentin, Monica Facco, Federica Frezzato, et al.
Plos One|October 3, 2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cellsSabrina Manni, Alessandra Brancalion, Elisa Mandato, et al.
British Journal of Haematology|April 19, 2017
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cellsVeronica Martini, Cristina Gattazzo, Federica Frezzato, et al.
Cancers|November 13, 2021
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic LeukemiaFederica Frezzato, Andrea Visentin, Filippo Severin, et al.
Cancer Reports (Hoboken, N.J.)|April 25, 2024
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenarioNicolò Danesin, Greta Scapinello, Dorella Del Prete, et al.
Hematological Oncology|July 24, 2019
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemiaAndrea Visentin, Marina Deodato, Francesca R Mauro, et al.
Scientific Reports|May 2, 2025
A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cellsCristina Poggiana, Alessandro Francesco Piazza, Cristina Catoni, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
European Journal of Haematology|October 20, 2022
IDH2<sup>R172</sup> mutation in angioimmunoblastic T-cell lymphoma: A retrospective multicenter case seriesMarcello Riva, Maria Chiara Tisi, Roberta Bertorelle, et al.
Pageof 21